TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00739752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Framed-Recommended
Description: Subjects receive information only and are recommended the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed-Offered
Description: Subjects receive gain-framed messages and are offered the vaccine.
Study: NCT02338310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Choice of AI is according to centre policy; any brand can be used
Study: NCT03109899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sex Pro mobile Application
Description: Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
Study: NCT03441152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation
Study: NCT02801734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQUIP
Description: Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
Study: NCT02103985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39823277
Description: Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39823277
Description: Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
Study: NCT03642158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
Study: NCT03055273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOCIABLE
Description: SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOCIABLE
Description: SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
Study: NCT04148469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation.
Description: Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo needling
Description: No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
Study: NCT04217239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIE Ivor- Lewis
Description: minimally invasive esophagectomy (MIE) with intrathoracic anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIE McKeown
Description: minimally invasive esophagectomy (MIE) with cervical anastomosis
Study: NCT03733301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid
Description: Administered as standard-of-care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT00320801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Study: NCT03545360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-703 (Treatment group)
Description: Treatment with BTL-703 device
Study: NCT04009681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
Study: NCT00852865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus farciminis
Description: 1 capsule per day. Each capsule containing 4\*109 CFU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day
Study: NCT02883374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Study: NCT00844012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)
Description: Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic OC (clormadinone acetate plus ethinil-estradiol)
Description: Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
Study: NCT03512301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAMCI
Description: CAMCI battery of computerized tasks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAMCI
Description: CAMCI battery of computerized tasks
Study: NCT02227004

Intervention type: DIAGNOSTIC_TEST
Intervention: Perform MRI in patients with pacemaker or ICD
Description: Perform MRI in patients with pacemaker or ICD
Study: NCT03245125

Intervention type: BEHAVIORAL
Intervention: High-intensity interval training
Description: Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.

Intervention type: BEHAVIORAL
Intervention: High-intensity interval training
Description: Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.

Intervention type: BEHAVIORAL
Intervention: High-intensity interval training
Description: Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.

Intervention type: BEHAVIORAL
Intervention: High-intensity interval training
Description: Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
Study: NCT01975363

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Description: Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Description: Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Dietary Intake
Description: Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Dietary Intake
Description: Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Log
Description: All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Log
Description: All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
Study: NCT01262859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
Study: NCT02737579

Intervention type: PROCEDURE
Group type: OTHER
Intervention: XFM guidance
Description: X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
Study: NCT01579435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
Study: NCT01088334

Intervention type: OTHER
Intervention: screening
Description: CT-Chest/abdomen and mammography in women
Study: NCT05100914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Couple-based family nursing
Description: Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Couple-based family nursing
Description: Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
Study: NCT00732875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab + methotrexate (MTX)
Description: Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
Study: NCT03666871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Expanded unmodified autologous CD4+ T cells
Description: Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
Study: NCT03032263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy for nasal intubation
Description: The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
Study: NCT04009681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
Study: NCT03032263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: These patients will be nasally intubated for their procedure via direct laryngoscopy
Study: NCT02300259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally
Study: NCT00739752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed-Recommended
Description: Subjects receive gain-framed messages and are recommended the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed-Offered
Description: Subjects receive loss-framed messages and are offered the vaccine.
Study: NCT02300259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Administered orally
Study: NCT02543307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-led Patient Pathways
Description: The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
Study: NCT03249272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
Study: NCT01153997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.